New combo therapy before surgery shows promise against lung and liver cancers
NCT ID NCT04123379
First seen Jun 02, 2026 · Last updated Jun 12, 2026 · Updated 2 times
Summary
This study tested whether adding an experimental drug (either a CCR2/5-inhibitor or an anti-IL-8) to the immunotherapy nivolumab before and after surgery could help shrink tumors and improve long-term survival in people with non-small cell lung cancer or liver cancer. 48 adults who were candidates for surgery took part. The goal was to see a strong immune response in the removed tumor and better survival rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.